Cardiometabolic disorders and mild cognitive impairment in White and Black Americans

IF 11.1 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-09-09 DOI:10.1002/alz.70642

Voyko Kavcic, Mohammad Turaani, Subhamoy Pal, Jonathan M. Reader, Bruno Giordani

{"title":"Cardiometabolic disorders and mild cognitive impairment in White and Black Americans","authors":"Voyko Kavcic, Mohammad Turaani, Subhamoy Pal, Jonathan M. Reader, Bruno Giordani","doi":"10.1002/alz.70642","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia. We investigate associations among cardiovascular and metabolic disorders (hypertension, diabetes mellitus, and hyperlipidemia) and diagnosis (normal; amnestic [aMCI]; and non-amnestic [naMCI]).</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>Multinomial logistic regressions of participant data (<i>N</i> = 8737; age = 70.9 ± 7.5 years) from the National Alzheimer's Coordinating Center Uniform Dataset Version 3 protocol cohort were used.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Controlling for demographic/health variables, individuals with aMCI, though not naMCI, showed a higher likelihood of hypertension, diabetes, and hyperlipidemia compared to cognitively normal counterparts, though no differences between aMCI/naMCI. Black Americans, regardless of cognitive status, were more likely to fall into hypertension and diabetes groups compared to White Americans.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>These findings underscore the critical role of diagnosis and race in MCI diagnosis and care, emphasizing the need for tailored interventions to address inequities and reduce the risk of progression to dementia.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>The study leverages a large, racially diverse cohort from the NACC database. </li>\n \n <li>Black Americans with non-amnestic mild cognitive impairment(naMCI) show highest comorbidity burden.</li>\n \n <li>No significant differences in comorbidity burden between amnestic MCI (aMCI) and naMCI subtypes. </li>\n \n <li>Education is protective, but less so for Black American individuals.</li>\n \n <li>Older age, male sex, body mass index (BMI), and low education associate with increased risk for comorbidities.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 9","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70642","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70642","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia. We investigate associations among cardiovascular and metabolic disorders (hypertension, diabetes mellitus, and hyperlipidemia) and diagnosis (normal; amnestic [aMCI]; and non-amnestic [naMCI]).

METHODS

Multinomial logistic regressions of participant data (N = 8737; age = 70.9 ± 7.5 years) from the National Alzheimer's Coordinating Center Uniform Dataset Version 3 protocol cohort were used.

RESULTS

Controlling for demographic/health variables, individuals with aMCI, though not naMCI, showed a higher likelihood of hypertension, diabetes, and hyperlipidemia compared to cognitively normal counterparts, though no differences between aMCI/naMCI. Black Americans, regardless of cognitive status, were more likely to fall into hypertension and diabetes groups compared to White Americans.

DISCUSSION

These findings underscore the critical role of diagnosis and race in MCI diagnosis and care, emphasizing the need for tailored interventions to address inequities and reduce the risk of progression to dementia.

Highlights

The study leverages a large, racially diverse cohort from the NACC database.
Black Americans with non-amnestic mild cognitive impairment(naMCI) show highest comorbidity burden.
No significant differences in comorbidity burden between amnestic MCI (aMCI) and naMCI subtypes.
Education is protective, but less so for Black American individuals.
Older age, male sex, body mass index (BMI), and low education associate with increased risk for comorbidities.

Abstract Image

查看原文本刊更多论文

美国白人和黑人的心脏代谢障碍和轻度认知障碍

轻度认知障碍（MCI）是介于正常衰老和痴呆之间的过渡阶段。我们研究了心血管和代谢疾病（高血压、糖尿病和高脂血症）与诊断（正常、遗忘[aMCI]和非遗忘[naMCI]）之间的关系。方法对来自国家阿尔茨海默病协调中心统一数据集版本3协议队列的参与者数据（N = 8737，年龄= 70.9±7.5岁）进行多项logistic回归。结果：控制人口统计学/健康变量，与认知正常的个体相比，aMCI个体（而非naMCI）表现出更高的高血压、糖尿病和高脂血症的可能性，尽管aMCI/naMCI之间没有差异。与美国白人相比，无论认知状况如何，美国黑人更容易成为高血压和糖尿病人群。这些研究结果强调了诊断和种族在轻度认知障碍诊断和治疗中的关键作用，强调需要有针对性的干预措施来解决不平等问题并降低进展为痴呆的风险。该研究利用了NACC数据库中一个庞大的、种族多样化的队列。非遗忘性轻度认知障碍（naMCI）的美国黑人表现出最高的合并症负担。遗忘型MCI （aMCI）和naMCI亚型的共病负担无显著差异。教育是有保护作用的，但对美国黑人来说就不那么有保护作用了。年龄较大、男性、身体质量指数（BMI）和受教育程度低与合并症的风险增加有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.